ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Finasteride

Also written as “Finasteride 5 mg Tablet, single dose”, “minoxidil + finasteride” and “Finasteride 5 mg tablets”.

Its studies are mostly in Alopecia · Prostatic Hyperplasia · Acne Vulgaris, led by 9 companies.

Drug pageFinasteride: every studyMany companies study it; this page follows only the 17 they lead. All 49 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 27, 201017 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since May 27, 2010May 27, 2010none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 3, 2009Feb 3, 2009none ahead
Il-Yang Pharm.its history only21 open or runningphase 3since Oct 6, 2026Dec 11, 2025Aug 31, 2027phase 3 · NCT07870759
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Almirallits history only10 open or runningphase 1since Jun 1, 2016Jun 1, 2016none ahead
Beijing Dayspring Pharmaceutical Technologyits history only10 open or runningphase 2since Jul 1, 2025Jul 1, 2025none ahead
Eloracits history only10 open or runningphase 2since Jul 10, 2015Jul 10, 2015none ahead
HairDxits history only10 open or runningphase 1since Jan 16, 2010Jan 16, 2010none ahead
Merck10 open or runningphase 3since Feb 13, 2012Feb 13, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2012First study: phase 3 study in Prostatic HyperplasiaFirst studyNCT01534351 · 1 enrolled

TargetBeta

SRD5A2 →read by rule
“Steroid 5-alpha-reductase 2 inhibitor”ChEMBL 37, by rule

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01534351Prostatic Hyperplasia3TerminatedNov 18, 20131

How it is read

Names in the registry

  • “Finasteride”, 6 entries
  • “Finasteride 5 mg Tablet, single dose”, 3 entries
  • “minoxidil + finasteride”, 2 entries
  • “Finasteride 5 mg tablets”, 2 entries
  • “Finasteride Tablets 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.